GBP13.41
0.30% today
London, Aug 08, 05:35 pm CET
ISIN
GB0009223206
Symbol
SN

Smith & Nephew Stock price

GBP13.41
+2.41 21.86% 1M
+3.52 35.67% 6M
+3.65 37.40% YTD
+1.93 16.81% 1Y
+3.43 34.40% 3Y
-0.35 2.57% 5Y
+3.88 40.78% 10Y
+9.79 270.30% 20Y
London, Closing price Fri, Aug 08 2025
-0.04 0.30%

Key metrics

Basic
Market capitalization
GBP11.7b
Enterprise Value
GBP13.7b
Net debt
GBP2.0b
Cash
GBP460.5m
Shares outstanding
874.4m
Valuation (TTM | estimate)
P/E
38.4 | 17.1
P/S
2.7 | 2.5
EV/Sales
3.2 | 3.0
EV/FCF
30.4
P/B
3.0
Dividends
DPS
GBP0.29
Yield 1Y | 5Y
2.1% | 2.5%
Growth 1Y | 5Y
-5.9% | -0.9%
Payout 1Y | 3Y
81.7% | 118.8%
Increased
0 Years
Financials (TTM | estimate)
Revenue
GBP4.3b | GBP4.6b
EBITDA
GBP758.1m | GBP1.2b
EBIT
GBP625.7m | GBP809.5m
Net Income
GBP306.5m | GBP688.6m
Free Cash Flow
GBP450.9m
Growth (TTM | estimate)
Revenue
4.7% | 7.4%
EBITDA
24.7% | 45.3%
EBIT
37.9% | 22.3%
Net Income
56.7% | 124.7%
Free Cash Flow
234.8%
Margin (TTM | estimate)
Gross
69.6%
EBITDA
17.5% | 26.1%
EBIT
14.5%
Net
7.1% | 14.8%
Free Cash Flow
10.4%
Financial Health
Equity Ratio
50.9%
Return on Equity
7.8%
ROCE
9.5%
ROIC
8.4%
Debt/Equity
0.6
More
EPS
GBP0.4
FCF per Share
GBP0.5
Short interest
131.0%
Employees
17k
Rev per Employee
GBP250.0k
Show more

Is Smith & Nephew a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,025 stocks worldwide.

Smith & Nephew Stock Analysis

Unlock Scores for Free

Analyst Opinions

25 Analysts have issued a Smith & Nephew forecast:

13x Buy
52%
11x Hold
44%
1x Sell
4%

Analyst Opinions

25 Analysts have issued a Smith & Nephew forecast:

Buy
52%
Hold
44%
Sell
4%

Financial data from Smith & Nephew

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
4,323 4,323
5% 5%
100%
- Direct Costs 1,312 1,312
2% 2%
30%
3,010 3,010
6% 6%
70%
- Selling and Administrative Expenses 2,037 2,037
3% 3%
47%
- Research and Development Expense 215 215
15% 15%
5%
758 758
25% 25%
18%
- Depreciation and Amortization 132 132
14% 14%
3%
EBIT (Operating Income) EBIT 626 626
38% 38%
14%
Net Profit 307 307
57% 57%
7%

In millions GBP.

Don't miss a Thing! We will send you all news about Smith & Nephew directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Smith & Nephew Plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics; Sports Medicine and ENT; and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies and ENT. The Advanced Wound Management segment comprises advanced wound care, advanced wound bioactives and advanced wound devices businesses. The company was founded by Thomas James Smith in 1856 and is headquartered in London, the United Kingdom.

Head office United Kingdom
CEO Deepak Nath
Employees 17,349
Founded 1856
Website www.smith-nephew.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today